Drug Profile
Selegiline orally disintegrating tablets
Alternative Names: Xilopar; ZelaparLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator RP Scherer
- Class Analgesics; Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
- 18 Jul 2006 Launched for Parkinson's disease in USA (PO)